RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Altl, Is there a link to that info? Thanks.



Neurolixis is a new startup launched in June 2011. There is some interesting info at the Neurolixis website (see below). They have apparently hired a CEO, but don't name him, only saying "details to be announced". Also, not that it means anything, but one of the company principals (Tancredi) got his PhD in the UK, and worked at Servier. Years ago Varney also spent some time at Servier in a research position -


http://www.neurolixis.com/management.html




>>> President and Chief Executive Officer.

Our CEO has spent over two decades in pharmaceutical research and previously held senior positions in biopharmaceutical companies
(details to be announced).




Adrian Newman-Tancredi Ph.D.

Dr. Newman-Tancredi has broad expertise in neuroscience drug discovery and early pre-clinical development. He was previously Director of Neurobiology and Project Manager at Pierre Fabre Laboratories. More... (see below)



Herbert Y. Meltzer, M.D.

Prof. Meltzer has extensive experience in translational pharmacology at both the bench and the bedside, having discovered the shared mechanism of action of clozapine-like atypical antipsychotic drugs and pioneered their use in the treatment of schizophrenia and bipolar disorder. More...


____________________________________________________



Adrian Newman-Tancredi Ph.D.

Dr. Newman-Tancredi has over 20 years' experience of neuroscience research and drug discovery. Prior to joining Neurolixis, he was Director of Neurobiology and Project Manager at Pierre Fabre Laboratories where he led multi-disciplinary programs that successfully identified and characterized novel antipsychotics, antidepressants and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology research group at the Servier Research Institute where he was responsible for screening of NCEs and investigating signal transduction mechanisms of monoamine receptors.

Dr. Newman-Tancredi has extensive experience of project team management, integrating medicinal chemistry, pharmacology, early ADMET and preclinical development, and building international collaborations with academic researchers.

Dr. Newman-Tancredi has published over 130 research reports, co-authored patents on NCEs and given presentations to a wide variety of audiences. He serves on the Editorial Board of the International Journal of Neuropsychopharmacology and as an independent neuropharmacology and drug discovery consultant (www.neuroact.com). Dr. Newman-Tancredi received his B.Sc. with honours in Biochemistry and his Ph.D. in neuropharmacology from the University of Kent at Canterbury, U.K. He is bi-national (anglo-italian) and tri-lingual (English, French, Italian).

<<<